Pith. sign in

REVIEW 4 major objections 5 minor 1 cited by

Recent Developments in GNNs for Drug Discovery

T0 review · 4 major / 5 minor · reviewed 2026-08-07 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read This review claims that molecular graph representation learning has become the dominant paradigm across molecule generation, property prediction, and drug-drug interaction prediction.

desk verdict Useful but uneven survey of GNNs for drug discovery; the 'dominant paradigm' conclusion overreaches, and a few taxonomy errors need fixing. read the letter →

arxiv 2506.01302 v1 pith:OPREA3HA submitted 2025-06-02 cs.LG q-bio.QM

Zhengyu Fang , Xiaoge Zhang , Anyin Zhao , Xiao Li , Huiyuan Chen , Jing Li This is my paper
classification cs.LGq-bio.QM
keywords drugdiscoverygraphneuralnetworksmolecularrepresentationlearningmoleculegenerationpropertypredictiondrug-druginteractionself-supervisedbenchmarkdatasets
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This review tries to establish that graph neural networks have become the dominant computational approach in drug discovery, uniting molecule generation, molecular property prediction, and drug-drug interaction prediction under molecular graph representation learning. It surveys work published since 2021, organizing methods by input type (2D graphs, 3D graphs, multi-molecule complexes) and by task, and collects the benchmark datasets that support these applications. The authors argue that GNNs naturally capture intricate molecular patterns, and that recent advances such as self-supervised pre-training, few-shot learning, and multi-modal fusion have made these models more accurate and generalizable. If the claim holds, new drug discovery systems will be built around GNNs operating on molecular graphs, with data quality, interpretability, and multi-omics integration as the main remaining bottlenecks.

What carries the argument

The central object is the molecular graph, with atoms as nodes and bonds as edges, optionally augmented with three-dimensional coordinates and auxiliary information. GNN message passing aggregates information from neighboring nodes to produce latent node and molecular representations, which are then used for generation, property prediction, or interaction prediction. The review's organizing machinery is a taxonomy that crosses input types (2D graphs, 3D graphs, multi-molecule complexes) with tasks and learning strategies such as self-supervised pre-training and few-shot learning; this taxonomy carries the argument by grouping all surveyed methods and revealing the field's common trends.

What would settle it

A reader could reproduce the paper's tables from the original sources: if a substantial share of recent state-of-the-art methods in the three tasks are not GNN-based, or if the table's classifications do not match the cited papers (for instance, SQUID is listed as protein-ligand generation although the text describes it as shape-conditioned and target-agnostic, and DeepDDS is cited as [107] in the text but [109] in the appendix), the taxonomy and the dominance claim would need revision.

Watch

Extended reading notes

Core claim

The paper's central claim is that molecular graph representation learning has become a dominant paradigm in computational drug discovery, with evidence drawn from three application areas: molecule generation, molecular property prediction, and drug-drug interaction prediction. It argues that GNNs, by operating directly on molecular graphs rather than one-dimensional string representations, capture chemical structure and complex molecular patterns more effectively, and that recent progress has shifted toward 3D molecular graphs, pre-trained and few-shot learning strategies, and multi-modal input fusion. The review presents its taxonomy of methods and benchmark datasets as a map of this emerging mainstream, and identifies data scarcity, model interpretability, and integration of multi-omics data as the central open challenges.

Load-bearing premise

The review's central claim depends on the assumption that its selected papers and their categorization accurately represent the primary literature on GNNs in drug discovery; missed or misclassified works could make the dominance claim overstate the field's actual state.

Editorial extensions

If this is right

  • If molecular graph representation learning is dominant, new drug discovery systems will likely treat molecular graphs as the default input representation for generation and prediction tasks.
  • The shift toward 3D molecular graphs implies that property and interaction prediction will continue to adopt geometry-aware architectures that exploit distances, angles, and conformations.
  • Self-supervised pre-training and few-shot learning will remain standard tools for coping with scarce labeled data, especially for toxicity and clinical endpoints.
  • Drug-drug interaction prediction will increasingly incorporate patient medical histories to produce personalized and context-aware medication recommendations.
  • Data heterogeneity, interpretability, and multi-omics integration are the next frontiers that GNN-based drug discovery must address to move from benchmarks to real-world use.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • The 'dominant paradigm' claim is an assessment of the reviewed literature rather than a quantitative comparison; a systematic benchmark covering both GNN and non-GNN methods on common datasets would test it directly.
  • The taxonomy's internal inconsistencies (SQUID listed as protein-ligand based despite being described as shape-conditioned and target-agnostic, and the DeepDDS citation appearing as [107] in the text but [109] in the appendix) suggest readers should verify details against the original papers before using the tables as a guide.
  • The emphasis on pre-training and multi-modal fusion hints that future GNN drug discovery models may integrate sequence, graph, and 3D geometry into a single pretraining framework, an extension the authors mention but do not develop.
  • If interpretability remains unresolved, adoption of GNNs in regulated pharmaceutical settings may depend on explainable model variants as much as on predictive accuracy.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 5 minor

Summary. This manuscript is a survey of graph neural network methods applied to three drug-discovery tasks: molecule generation, molecular property prediction, and drug-drug interaction prediction. It organizes recent GNN-based methods by input type and task, catalogs commonly used benchmark datasets, provides a table of code URLs, and concludes that molecular graph representation learning has become a dominant paradigm across these applications.

Significance. If its organizational and bibliographic claims were accurate, the survey would serve as a useful entry point to GNN-based drug discovery by assembling a broad set of methods, datasets, and code links in one place. The paper makes no empirical claims and contains no derivations, and it offers no machine-checked artifacts; its contribution is purely taxonomic and bibliographic. That makes the correctness of its categorization and reference list load-bearing. The strengths are the breadth of coverage, the inclusion of code URLs, and the concise descriptions of benchmark datasets.

major comments (4)
  1. [Section 7] The central concluding claim that molecular graph representation learning has 'become a dominant paradigm' is not established by the evidence presented. The review includes only GNN-based methods, by design, and contains no comparison with or systematic discussion of non-GNN approaches (e.g., sequence-based transformers, diffusion or flow models, or LLM-based methods) that have also advanced molecule generation, property prediction, and interaction prediction. To support the word 'dominant,' the authors would need to broaden the survey to include representative non-GNN methods or explicitly qualify the claim as a statement about trends within GNN-based work.
  2. [Section 3.1] ConfVAE [6] and von MisesNet [7] are presented as unconstrained molecule generation methods, but both papers address molecular conformation generation (generating 3D geometries of a given molecular graph), not generation of novel chemical entities. This conflicts with the definition in Section 1.1, where molecule generation produces 'valid but different molecules' evaluated by validity and variety. Placing these methods under unconstrained generation inflates the molecule-generation evidence for GNNs, and they should be moved to a separate conformation-generation category or explicitly reframed.
  3. [Table 1, SQUID row] SQUID is listed under 'Ligand-Protein Based Generation,' but Section 3.3 describes it as shape-conditioned generation from an input 3D shape treated as a point cloud, with no protein binding site as input. This is internally inconsistent and misleading for readers who use the table as a guide. The row should be reclassified or the description in Section 3.3 should be corrected.
  4. [Appendix Table 3 vs. Section 5.3] The reference number for DeepDDS is inconsistent: Section 5.3 and Table 1 cite it as [107], while Appendix Table 3 lists 'DeepDDS [109]' even though reference [109] is SSF-DDI and the SSF-DDI URL appears on the same line. This is a concrete citation error in a survey whose main contribution is bibliographic organization, and the numbering in the appendix should be checked and corrected.
minor comments (5)
  1. [References] References [6] and [61] are the same paper (Xu et al., ICML 2021) but are listed as two distinct entries; one should be removed or cross-referenced.
  2. [Section 6.4.2] The sentence 'by appling NLP algorithms' contains a typo and should read 'by applying NLP algorithms.'
  3. [Section 6.1] The sentence 'the two database' should read 'the two databases.'
  4. [Section 6.4.1] The count '1.440 protein-nucleic acid complex' should be written as '1,440 protein-nucleic acid complexes.'
  5. [Throughout] The name 'V onMisesNet' appears with a stray space in several places; it should be 'von MisesNet' to match the cited work.

Circularity Check

0 steps flagged · score 0.0 of 10

No circularity: the survey's organization is independent of its self-citations, and its dominance claim is an inductive summary, not a construction.

full rationale

This paper is a literature survey, not a derivation. It makes no empirical predictions, fits no parameters, and proves no theorems, so the standard circularity patterns (self-definitional equivalence, fitted input called prediction, renamed result) do not apply. The central claim in Section 7 that molecular graph representation learning 'has become a dominant paradigm' is a summary of the reviewed GNN literature; it is not derived by construction from any definition or equation. The survey does contain several self-citations (e.g., refs [3], [4], [17], [29], [48], [49], [106]), but each is used as background or as an example of an approach, and none is the sole support for the taxonomy or the concluding claim. The taxonomy and dataset tables are the paper's contribution, and they are assembled from external primary sources. Concern about selection bias (the review only includes GNN-based works, so the dominance claim is not established against non-GNN baselines) is a correctness and scope issue, not circularity. Similarly, the apparent misclassification of conformer-generation papers under unconstrained generation and the DeepDDS/SSF-DDI reference mismatch in Table 3 are factual accuracy issues. No load-bearing step reduces to its own input, so the circularity score is 0.

Assumptions & free parameters 0 free parameters · 0 assumptions · 0 invented entities

This is a review; it introduces no new model parameters, axioms, or entities. It relies on standard domain knowledge and the cited literature.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Recent Developments in GNNs for Drug Discovery." pith.science (2026). https://pith.science/paper/OPREA3HA

@misc{pith2026250601302,
  author       = {Pith},
  title        = {Pith review of: Recent Developments in GNNs for Drug Discovery},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/OPREA3HA}},
  note         = {Machine review of arXiv:2506.01302}
}
read the original abstract

In this paper, we review recent developments and the role of Graph Neural Networks (GNNs) in computational drug discovery, including molecule generation, molecular property prediction, and drug-drug interaction prediction. By summarizing the most recent developments in this area, we underscore the capabilities of GNNs to comprehend intricate molecular patterns, while exploring both their current and prospective applications. We initiate our discussion by examining various molecular representations, followed by detailed discussions and categorization of existing GNN models based on their input types and downstream application tasks. We also collect a list of commonly used benchmark datasets for a variety of applications. We conclude the paper with brief discussions and summarize common trends in this important research area.

Figures

Figures reproduced from arXiv: 2506.01302 by the authors.

Figure 1
Figure 1. Various molecular representations commonly employed in computational drug discovery models: [PITH_FULL_IMAGE:figures/full_fig_p004_1.png] view at source ↗
Figure 2
Figure 2. The general framework of three different types of molecule generation processes. Molecular [PITH_FULL_IMAGE:figures/full_fig_p005_2.png] view at source ↗
Figure 3
Figure 3. The general framework for GNN-based drug property and interaction prediction. Three common [PITH_FULL_IMAGE:figures/full_fig_p007_3.png] view at source ↗
Figures from the paper (1 more)
Figure 4
Figure 4. Figure 4: The general process of DDI prediction based on GNN models. Possible inputs for the general DDI [PITH_FULL_IMAGE:figures/full_fig_p012_4.png]

Discussion (0). Sign in to comment.

Forward citations

Cited by 1 Pith paper

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score. Full citation record

  1. A Spectral Framework for Graph Neural Operators: Convergence Guarantees and Tradeoffs

    stat.ML 2025-10 conditional novelty 2.0 of 10

    Three existing graphon sampling bounds give GNN eigenvalue-convergence rates of (log n)^-1/4, sqrt(log n/n), and (log n/n)^1/4; the note unifies and tests them, finding all loose.

Reference graph

Works this paper leans on

134 extracted references · 78 canonical work pages · cited by 1 Pith paper

  1. [107]

    & Liu, H

    Wang, J., Liu, X., Shen, S., Deng, L. & Liu, H. DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations.Briefings in Bioinformatics23(2021)

    work page 2021

  2. [109]

    Zhu, J.et al.SSF-DDI: a deep learning method utilizing drug sequence and substructure features for drug–drug interaction prediction.BMC Bioinformatics25(2024)

    work page 2024

  3. [7]

    Swanson, K., Williams, J. L. & Jonas, E. M. V on mises mixture distributions for molecular confor- mation generation. InInternational Conference on Machine Learning, 33319–33342 (PMLR, 2023)

    2023

  4. [1]

    New drugs cost us 2.6 billion to develop.Nature reviews drug discovery(2014)

    Mullard, A. New drugs cost us 2.6 billion to develop.Nature reviews drug discovery(2014)

    2014

  5. [2]

    Gawehn, E., Hiss, J. A. & Schneider, G. Deep learning in drug discovery.Molecular informatics35, 3–14 (2016)

    2016

  6. [3]

    Chen, H. & Li, J. Modeling relational drug-target-disease interactions via tensor factorization with multiple web sources. InThe World Wide Web Conference, 218–227 (2019)

    2019

  7. [4]

    Chen, H. & Li, J. DrugCom: Synergistic discovery of drug combinations using tensor decomposition. In2018 IEEE International Conference on Data Mining (ICDM), 899–904 (IEEE, 2018)

    2018

  8. [5]

    Wang, W., Yang, S., Zhang, X. & Li, J. Drug repositioning by integrating target information through a heterogeneous network model.Bioinformatics30, 2923–2930 (2014)

    2014

Show all 134 references
  1. [8]

    InInternational Conference on Machine Learning(2021)

    Maziarz, K.et al.Learning to extend molecular scaffolds with structural motifs. InInternational Conference on Machine Learning(2021)

    2021

  2. [9]

    InInternational Conference on Learning Representations (ICLR)(2023)

    Geng, Z.et al.De Novo molecular generation via connection-aware motif mining. InInternational Conference on Learning Representations (ICLR)(2023). 23

    2023

  3. [10]

    & Hwang, S

    Lee, S., Lee, S., Kawaguchi, K. & Hwang, S. J. Drug discovery with dynamic goal-aware fragments. InInternational Conference on Machine Learning, 26731–26751 (PMLR, 2024)

    2024

  4. [11]

    & Peng, J

    Luo, S., Guan, J., Ma, J. & Peng, J. A 3D generative model for structure-based drug design.Advances in Neural Information Processing Systems34, 6229–6239 (2021)

    2021

  5. [12]

    Liu, M., Luo, Y ., Uchino, K., Maruhashi, K. & Ji, S. Generating 3D molecules for target protein binding. InInternational Conference on Machine Learning, 13912–13924 (PMLR, 2022)

    2022

  6. [13]

    InInterna- tional Conference on Machine Learning, 17644–17655 (PMLR, 2022)

    Peng, X.et al.Pocket2Mol: Efficient molecular sampling based on 3d protein pockets. InInterna- tional Conference on Machine Learning, 17644–17655 (PMLR, 2022)

    2022

  7. [14]

    & Liu, Q

    Zhang, Z., Min, Y ., Zheng, S. & Liu, Q. Molecule generation for target protein binding with structural motifs. InThe eleventh international conference on learning representations(2023)

    2023

  8. [15]

    & Coley, C

    Adams, K. & Coley, C. W. Equivariant shape-conditioned generation of 3d molecules for ligand-based drug design. InThe Eleventh International Conference on Learning Representations(2022)

    2022

  9. [16]

    Lim, J., Ryu, S., Kim, J. W. & Kim, W. Y . Molecular generative model based on conditional varia- tional autoencoder for de novo molecular design.Journal of Cheminformatics10(2018)

    2018

  10. [17]

    Chen, H. & Li, J. Learning data-driven drug-target-disease interaction via neural tensor network. In International joint conference on artificial intelligence (IJCAI)(2020)

    2020

  11. [18]

    & Zhou, J

    Sun, M., Xing, J., Wang, H., Chen, B. & Zhou, J. MoCL: data-driven molecular fingerprint via knowledge-aware contrastive learning from molecular graph. InProceedings of the 27th ACM SIGKDD conference on knowledge discovery & data mining, 3585–3594 (2021)

    2021

  12. [19]

    Ju, W.et al.Few-shot molecular property prediction via hierarchically structured learning on relation graphs.Neural Networks163, 122–131 (2023)

    2023

  13. [20]

    & Yao, Q

    Wu, S., Wang, Y . & Yao, Q. PACIA: parameter-efficient adapter for few-shot molecular property pre- diction. InProceedings of the Thirty-Third International Joint Conference on Artificial Intelligence, 5208–5216 (2024)

    2024

  14. [21]

    Wu, Z.et al.MoleculeNet: a benchmark for molecular machine learning.Chemical Science9, 513–530 (2018)

    2018

  15. [22]

    & Cai, L

    Yang, S., Li, Z., Song, G. & Cai, L. Deep molecular representation learning via fusing physical and chemical information.Advances in Neural Information Processing Systems34, 16346–16357 (2021)

    2021

  16. [23]

    InThe Eleventh Interna- tional Conference on Learning Representations(2023)

    Zhu, J.et al.O-GNN: incorporating ring priors into molecular modeling. InThe Eleventh Interna- tional Conference on Learning Representations(2023)

    2023

  17. [24]

    Jones, D.et al.Improved protein-ligand binding affinity prediction with structure-based deep fusion inference.Journal of chemical information and modeling61, 1583–1592 (2021)

    2021

  18. [25]

    & Uhler, C

    Jin, W., Sarkizova, S., Chen, X., Hacohen, N. & Uhler, C. Unsupervised protein-ligand binding energy prediction via neural euler’s rotation equation.Advances in Neural Information Processing Systems36, 33514–33528 (2023). 24

    2023

  19. [26]

    & Tang, J

    Zhang, Y ., Cai, H., Shi, C., Zhong, B. & Tang, J. E3Bind: An end-to-end equivariant network for protein-ligand docking.International Conference on Learning Representations (ICLR)(2022)

    2022

  20. [27]

    & Chen, C

    Yang, Z., Zhong, W., Zhao, L. & Chen, C. Y .-C. MGraphDTA: deep multiscale graph neural network for explainable drug-target binding affinity prediction.Chemical science13, 816–833 (2022)

    2022

  21. [28]

    InInterna- tional Conference on Machine Learning, 18852–18871 (PMLR, 2023)

    Lee, N.et al.Conditional graph information bottleneck for molecular relational learning. InInterna- tional Conference on Machine Learning, 18852–18871 (PMLR, 2023)

    2023

  22. [29]

    Chen, H., Cheng, F. & Li, J. iDrug: Integration of drug repositioning and drug-target prediction via cross-network embedding.PLoS computational biology16, e1008040 (2020)

    2020

  23. [30]

    InInternational Con- ference on Machine Learning, 20479–20502 (PMLR, 2022)

    St ¨ark, H.et al.3D infomax improves gnns for molecular property prediction. InInternational Con- ference on Machine Learning, 20479–20502 (PMLR, 2022)

    2022

  24. [31]

    P.et al.Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.Nature Communications10, 2674 (2019)

    Menden, M. P.et al.Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.Nature Communications10, 2674 (2019)

    2019

  25. [32]

    Preuer, K., Lewis, R., Hochreiter, S.et al.Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects.Nature Communications11, 5057 (2020)

    2020

  26. [33]

    Vilar, S.et al.Similarity-based modeling in large-scale prediction of drug-drug interactions.Nature protocols2147–2163 (2014)

    2014

  27. [34]

    Jiang, H.et al.Adverse drug reactions and correlations with drug-drug interactions: A retrospective study of reports from 2011 to 2020.Frontiers in Pharmacology13(2022)

    2022

  28. [35]

    & Kongkaew, C

    Dechanont, S., Maphanta, S., Butthum, B. & Kongkaew, C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis.Pharmacoepidemiology and Drug Safety23, 489–497 (2014)

    2014

  29. [36]

    & Wu, F.-X

    Wang, F., Lei, X., Liao, B. & Wu, F.-X. Predicting drug-drug interactions by graph convolutional network with multi-kernel.Briefings in Bioinformatics23, bbab511 (2022)

    2022

  30. [37]

    InInternational Joint Conference on Artificial Intelligence, vol

    Lyu, T.et al.MDNN: A multimodal deep neural network for predicting drug-drug interaction events. InInternational Joint Conference on Artificial Intelligence, vol. 3536 (2021)

    2021

  31. [38]

    Han, K.et al.A review of approaches for predicting drug–drug interactions based on machine learn- ing.Frontiers in Pharmacology12(2022)

    2022

  32. [39]

    InProceedings of the AAAI Conference on Artificial Intelligence, vol

    Xiong, Z.et al.Multi-relational contrastive learning graph neural network for drug-drug interaction event prediction. InProceedings of the AAAI Conference on Artificial Intelligence, vol. 37, 5339–5347 (2023)

    2023

  33. [40]

    & Sun, J

    Yang, C., Xiao, C., Ma, F., Glass, L. & Sun, J. SafeDrug: Dual molecular graph encoders for recom- mending effective and safe drug combinations. In30th International Joint Conference on Artificial Intelligence, 3735–3741 (International Joint Conferences on Artificial Intellige...

    2021

  34. [41]

    & Yan, J

    Yang, N., Zeng, K., Wu, Q. & Yan, J. MoleRec: Combinatorial drug recommendation with substructure-aware molecular representation learning. InProceedings of the ACM web conference 2023, 4075–4085 (2023). 25

    2023

  35. [42]

    & Wang, M

    Chen, Q., Li, X., Geng, K. & Wang, M. Context-aware safe medication recommendations with molec- ular graph and ddi graph embedding.Proceedings of the AAAI Conference on Artificial Intelligence 37, 7053–7060 (2023)

    2023

  36. [43]

    Cereto-Massagu ´e, A.et al.Molecular fingerprint similarity search in virtual screening.Methods71, 58–63 (2015)

    2015

  37. [44]

    SMILES, a chemical language and information system

    Weininger, D. SMILES, a chemical language and information system. 1. introduction to methodology and encoding rules.Journal of chemical information and computer sciences28, 31–36 (1988)

    1988

  38. [45]

    InInternational Conference on Learning Representations (ICLR)(2022)

    Liu, Y .et al.Spherical message passing for 3d molecular graphs. InInternational Conference on Learning Representations (ICLR)(2022)

    2022

  39. [46]

    & Liu, Y

    Jiao, R., Han, J., Huang, W., Rong, Y . & Liu, Y . Energy-motivated equivariant pretraining for 3d molecular graphs. InProceedings of the AAAI Conference on Artificial Intelligence, vol. 37, 8096– 8104 (2023)

    2023

  40. [47]

    Kipf, T. N. & Welling, M. Semi-supervised classification with graph convolutional networks. In International Conference on Learning Representations (ICLR)(2017)

    2017

  41. [48]

    InProceedings of the 44th international ACM SIGIR conference on research and development in information retrieval, 614–623 (2021)

    Chen, H.et al.Structured graph convolutional networks with stochastic masks for recommender sys- tems. InProceedings of the 44th international ACM SIGIR conference on research and development in information retrieval, 614–623 (2021)

    2021

  42. [49]

    M., Wang, F

    Chen, H., Yeh, C.-C. M., Wang, F. & Yang, H. Graph neural transport networks with non-local attentions for recommender systems. InProceedings of the ACM Web Conference 2022, 1955–1964 (2022)

    2022

  43. [50]

    InProceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining, 2850–2861 (2023)

    Xu, Z.et al.Kernel ridge regression-based graph dataset distillation. InProceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining, 2850–2861 (2023)

    2023

  44. [51]

    In2024 IEEE International Conference on Data Mining (ICDM), 875–880 (IEEE Computer Society, Los Alamitos, CA, USA, 2024)

    Wang, S.et al.Enhancing distribution and label consistency for graph out-of-distribution general- ization. In2024 IEEE International Conference on Data Mining (ICDM), 875–880 (IEEE Computer Society, Los Alamitos, CA, USA, 2024)

    2024

  45. [52]

    A.et al.Graph neural networks as a potential tool in improving virtual screening programs

    Alves, L. A.et al.Graph neural networks as a potential tool in improving virtual screening programs. Frontiers in Chemistry9(2022)

    2022

  46. [53]

    Visan, A. I. & Negut, I. Integrating artificial intelligence for drug discovery in the context of revolu- tionizing drug delivery.Life14, 233 (2024)

    2024

  47. [54]

    R., Diez, J

    Atance, S. R., Diez, J. V ., Engkvist, O., Olsson, S. & Mercado, R. De Novo drug design using reinforcement learning with graph-based deep generative models.Journal of Chemical Information and Modeling62, 4863–4872 (2022)

    2022

  48. [55]

    InNeural Information Processing Systems(2024)

    Xu, Z.et al.Discrete-state continuous-time diffusion for graph generation. InNeural Information Processing Systems(2024)

    2024

  49. [56]

    Mercado, R.et al.Graph networks for molecular design.Machine Learning: Science and Technology 2, 025023 (2021). 26

    2021

  50. [57]

    & Battaglia, P

    Li, Y ., Vinyals, O., Dyer, C., Pascanu, R. & Battaglia, P. Learning deep generative models of graphs. arXiv preprint arXiv:1803.03324(2018)

    2018 arXiv

  51. [58]

    H., Saffari, A

    Assouel, R., Ahmed, M., Segler, M. H., Saffari, A. & Bengio, Y . Defactor: Differentiable edge factorization-based probabilistic graph generation.arXiv preprint arXiv:1811.09766(2018)

    2018 arXiv

  52. [59]

    & Leskovec, J

    You, J., Ying, R., Ren, X., Hamilton, W. & Leskovec, J. GraphRNN: Generating realistic graphs with deep auto-regressive models. InInternational conference on machine learning, 5708–5717 (PMLR, 2018)

    2018

  53. [60]

    J., Segler, M

    Bradshaw, J., Paige, B., Kusner, M. J., Segler, M. & Hern ´andez-Lobato, J. M. A model to search for synthesizable molecules. In Wallach, H.et al.(eds.)Advances in Neural Information Processing Systems, vol. 32 (Curran Associates, Inc., 2019)

    2019

  54. [61]

    InInternational conference on machine learning, 11537–11547 (PMLR, 2021)

    Xu, M.et al.An end-to-end framework for molecular conformation generation via bilevel program- ming. InInternational conference on machine learning, 11537–11547 (PMLR, 2021)

    2021

  55. [62]

    Drug Discovery Today: Technologies37, 1–12 (2020)

    Wieder, O.et al.A compact review of molecular property prediction with graph neural networks. Drug Discovery Today: Technologies37, 1–12 (2020)

    2020

  56. [63]

    & Lee, C.-K

    Zhang, Z., Liu, Q., Wang, H., Lu, C. & Lee, C.-K. Motif-based graph self-supervised learning for molecular property prediction.Advances in Neural Information Processing Systems34, 15870–15882 (2021)

    2021

  57. [64]

    InProceed- ings of the AAAI conference on artificial intelligence, vol

    Fang, Y .et al.Molecular contrastive learning with chemical element knowledge graph. InProceed- ings of the AAAI conference on artificial intelligence, vol. 36, 3968–3976 (2022)

    2022

  58. [65]

    InProceedings of the Thirty-Second International Joint Conference on Artificial Intelligence, 4829–4837 (2023)

    Liu, L.et al.Multi-view contrastive learning hypergraph neural network for drug-microbe-disease as- sociation prediction. InProceedings of the Thirty-Second International Joint Conference on Artificial Intelligence, 4829–4837 (2023)

    2023

  59. [66]

    & Tang, B

    Zang, X., Zhao, X. & Tang, B. Hierarchical molecular graph self-supervised learning for property prediction.Communications Chemistry6, 34 (2023)

    2023

  60. [67]

    InProceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining, 2374–2385 (2023)

    Wang, S.et al.Federated few-shot learning. InProceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining, 2374–2385 (2023)

    2023

  61. [68]

    International Conference on Learning Representations (ICLR)(2023)

    Schimunek, J.et al.Context-enriched molecule representations improve few-shot drug discovery. International Conference on Learning Representations (ICLR)(2023)

    2023

  62. [69]

    Zhuang, X.et al.Graph sampling-based meta-learning for molecular property prediction.Interna- tional joint conference on artificial intelligence (IJCAI)(2023)

    2023

  63. [70]

    InInternational Conference on Machine Learning, 12055–12076 (PMLR, 2023)

    Guo, M.et al.Hierarchical grammar-induced geometry for data-efficient molecular property predic- tion. InInternational Conference on Machine Learning, 12055–12076 (PMLR, 2023)

    2023

  64. [71]

    & Yan, J

    Yang, N., Zeng, K., Wu, Q., Jia, X. & Yan, J. Learning substructure invariance for out-of-distribution molecular representations.Advances in Neural Information Processing Systems35, 12964–12978 (2022)

    2022

  65. [72]

    Vapnik, V .The nature of statistical learning theory(Springer science & business media, 2013). 27

    2013

  66. [73]

    InProceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining, 3615–3627 (2023)

    Zhu, J.et al.Dual-view molecular pre-training. InProceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining, 3615–3627 (2023)

    2023

  67. [74]

    L.et al.Interpretable chirality-aware graph neural network for quantitative structure activity relationship modeling in drug discovery

    Liu, Y . L.et al.Interpretable chirality-aware graph neural network for quantitative structure activity relationship modeling in drug discovery. InProceedings of the AAAI conference on artificial intelli- gence, vol. 37, 14356–14364 (2023)

    2023

  68. [75]

    InInternational Confer- ence on Learning Representations (ICLR)(OpenReview

    Liu, S.et al.Pre-training molecular graph representation with 3d geometry. InInternational Confer- ence on Learning Representations (ICLR)(OpenReview. net, 2022)

    2022

  69. [76]

    InProceedings of the 28th ACM SIGKDD conference on knowledge discovery and data mining, 2626–2636 (2022)

    Zhu, J.et al.Unified 2D and 3D pre-training of molecular representations. InProceedings of the 28th ACM SIGKDD conference on knowledge discovery and data mining, 2626–2636 (2022)

    2022

  70. [77]

    & Xiong, H

    Li, S., Zhou, J., Xu, T., Dou, D. & Xiong, H. Geomgcl: Geometric graph contrastive learning for molecular property prediction. InProceedings of the AAAI conference on artificial intelligence, vol. 36, 4541–4549 (2022)

    2022

  71. [78]

    & Tang, J

    Liu, S., Du, W., Ma, Z.-M., Guo, H. & Tang, J. A group symmetric stochastic differential equation model for molecule multi-modal pretraining. InInternational Conference on Machine Learning, 21497–21526 (PMLR, 2023)

    2023

  72. [79]

    & Yao, Q

    Wang, X., Zhao, H., Tu, W.-w. & Yao, Q. Automated 3D pre-training for molecular property pre- diction. InProceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining, 2419–2430 (2023)

    2023

  73. [80]

    Jiang, D.et al.InteractionGraphNet: a novel and efficient deep graph representation learning frame- work for accurate protein-ligand interaction predictions.Journal of medicinal chemistry64, 18209– 18232 (2021)

    2021

  74. [81]

    Li, X.-S.et al.Multiphysical graph neural network (MP-GNN) for COVID-19 drug design.Briefings in bioinformatics23, bbac231 (2022)

    2022

  75. [82]

    Wang, K., Zhou, R., Tang, J. & Li, M. GraphscoreDTA: optimized graph neural network for protein- ligand binding affinity prediction.Bioinformatics39, btad340 (2023)

    2023

  76. [83]

    Pei, Q.et al.FABind: Fast and accurate protein-ligand binding.Advances in Neural Information Processing Systems36, 55963–55980 (2023)

    2023

  77. [84]

    Liu, S.et al.A multi-grained group symmetric framework for learning protein-ligand binding dy- namics.arXiv preprint arXiv:2401.15122(2024)

    2024 arXiv

  78. [85]

    & Ding, Z

    Zhang, Y ., Huang, W., Wei, Z., Yuan, Y . & Ding, Z. EquiPocket: an E(3)-equivariant geometric graph neural network for ligand binding site prediction. InInternational Conference on Learning Representations (ICLR)(2024)

    2024

  79. [86]

    Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.Pharmacological Reviews58, 621–681 (2006)

    Chou, T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.Pharmacological Reviews58, 621–681 (2006)

    2006

  80. [87]

    Nature Biotechnology27, 659–666 (2009)

    Leh ´ar, J.et al.Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnology27, 659–666 (2009). 28

    2009

  81. [88]

    & Zhao, H

    Liu, T., Chu, T., Luo, X. & Zhao, H. Building a unified model for drug synergy analysis powered by large language models.Nature Communications16(2025)

    2025

  82. [89]

    A.et al.Systematic discovery of multicomponent therapeutics.Proceedings of the National Academy of Sciences100, 7977–7982 (2003)

    Borisy, A. A.et al.Systematic discovery of multicomponent therapeutics.Proceedings of the National Academy of Sciences100, 7977–7982 (2003)

    2003

  83. [90]

    S.et al.The novel combination of chlorpromazine and pentamidine exerts synergistic an- tiproliferative effects through dual mitotic action.Cancer Research67, 11359–11367 (2007)

    Lee, M. S.et al.The novel combination of chlorpromazine and pentamidine exerts synergistic an- tiproliferative effects through dual mitotic action.Cancer Research67, 11359–11367 (2007)

    2007

  84. [91]

    Han, K.et al.Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.Nature Biotechnology35, 463–474 (2017)

    2017

  85. [92]

    Pirmohamed, M.et al.Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients.BMJ329, 15–19 (2004)

    2004

  86. [93]

    & Kongkaew, C

    Dechanont, S., Maphanta, S., Butthum, B. & Kongkaew, C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis.Pharmacoepidemiology and Drug Safety23, 489–497 (2014)

    2014

  87. [94]

    N., Mamdani, M., Kopp, A., Laupacis, A

    Juurlink, D. N., Mamdani, M., Kopp, A., Laupacis, A. & Redelmeier, D. A. Drug-drug interactions among elderly patients hospitalized for drug toxicity.JAMA289, 1652 (2003)

    2003

  88. [95]

    V ., Harpaz, R., LePendu, P., Bauer-Mehren, A

    Iyer, S. V ., Harpaz, R., LePendu, P., Bauer-Mehren, A. & Shah, N. H. Mining clinical text for signals of adverse drug-drug interactions.Journal of the American Medical Informatics Association 21, 353–362 (2014)

    2014

  89. [96]

    Wu, P.et al.DDIW AS: High-throughput electronic health record-based screening of drug-drug inter- actions.Journal of the American Medical Informatics Association28, 1421–1430 (2021)

    2021

  90. [97]

    M., Zitnik, M

    Huang, K., Xiao, C., Glass, L. M., Zitnik, M. & Sun, J. SkipGNN: predicting molecular interactions with skip-graph networks.Scientific reports10, 21092 (2020)

    2020

  91. [98]

    & Shi, J.-Y

    Feng, Y .-H., Zhang, S.-W. & Shi, J.-Y . DPDDI: a deep predictor for drug-drug interactions.BMC bioinformatics21, 419 (2020)

    2020

  92. [99]

    & Zhao, J

    Xu, N., Wang, P., Chen, L., Tao, J. & Zhao, J. MR-GNN: Multi-resolution and dual graph neural net- work for predicting structured entity interactions. InProceedings of the Twenty-Eighth International Joint Conference on Artificial Intelligence, IJCAI-2019, 3968–3974 (Internati...

    2019

  93. [100]

    & Wang, W

    Bai, Y ., Gu, K., Sun, Y . & Wang, W. Bi-level graph neural networks for drug-drug interaction predic- tion.arXiv preprint arXiv:2006.14002(2020)

    2020 arXiv

  94. [101]

    Zhong, Y .et al.DDI-GCN: Drug-drug interaction prediction via explainable graph convolutional networks.Artificial Intelligence in Medicine144, 102640 (2023)

    2023

  95. [102]

    Gao, J., Wu, Z., Al-Sabri, R., Oloulade, B. M. & Chen, J. AutoDDI: Drug–drug interaction predic- tion with automated graph neural network.IEEE Journal of Biomedical and Health Informatics28, 1773–1784 (2024)

    2024

  96. [103]

    & Leskovec, J

    Zitnik, M., Agrawal, M. & Leskovec, J. Modeling polypharmacy side effects with graph convolutional networks.Bioinformatics34, i457–i466 (2018). 29

    2018

  97. [104]

    & Tang, J

    Deac, A., Huang, Y .-H., Veliˇckovi´c, P., Li`o, P. & Tang, J. Drug-drug adverse effect prediction with graph co-attention.stat1050, 2 (2019)

    2019

  98. [105]

    Liu, Q.et al.M2GCN: multi-modal graph convolutional network for modeling polypharmacy side effects.Applied Intelligence53, 6814–6825 (2022)

    2022

  99. [106]

    Chen, H., Iyengar, S. K. & Li, J. Large-scale analysis of drug combinations by integrating multiple heterogeneous information networks. InProceedings of the 10th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics, BCB ’19, 67–76 (ACM, 2019)

    2019

  100. [108]

    Zhang, P. & Tu, S. MGAE-DC: Predicting the synergistic effects of drug combinations through multi-channel graph autoencoders.PLOS Computational Biology19, e1010951 (2023)

    2023

  101. [110]

    Niu, D., Xu, L., Pan, S., Xia, L. & Li, Z. SRR-DDI: A drug–drug interaction prediction model with substructure refined representation learning based on self-attention mechanism.Knowledge-Based Systems285, 111337 (2024)

    2024

  102. [111]

    & Yeh, S.-J

    Ge, X., Lee, Y .-T. & Yeh, S.-J. MD-Syn: Synergistic drug combination prediction based on the multidimensional feature fusion method and attention mechanisms.arXiv preprint arXiv:2501.07884 (2025)

    2025 arXiv

  103. [112]

    Niu, D., Zhang, L., Zhang, B., Zhang, Q. & Li, Z. DAS-DDI: A dual-view framework with drug association and drug structure for drug–drug interaction prediction.Journal of Biomedical Informatics 156, 104672 (2024)

    2024

  104. [113]

    Knox, C.et al.DrugBank 6.0: the DrugBank knowledgebase for 2024.Nucleic Acids Research52, D1265–D1275 (2023)

    2023

  105. [114]

    Kim, S.et al.PubChem 2025 update.Nucleic Acids Research53, D1516–D1525 (2025)

    2025

  106. [115]

    E.et al.MIMIC-III, a freely accessible critical care database.Scientific data3, 1–9 (2016)

    Johnson, A. E.et al.MIMIC-III, a freely accessible critical care database.Scientific data3, 1–9 (2016)

    2016

  107. [116]

    Johnson, A. E. W.et al.MIMIC-IV, a freely accessible electronic health record dataset.Scientific Data10(2023)

    2023

  108. [117]

    Sudlow, C.et al.UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.PLoS medicine12, e1001779 (2015)

    2015

  109. [118]

    I.et al.ZINC-22-A free multi-billion-scale database of tangible compounds for ligand discovery.Journal of Chemical Information and Modeling63, 1166–1176 (2023)

    Tingle, B. I.et al.ZINC-22-A free multi-billion-scale database of tangible compounds for ligand discovery.Journal of Chemical Information and Modeling63, 1166–1176 (2023)

    2023

  110. [119]

    & G ´omez-Bombarelli, R

    Axelrod, S. & G ´omez-Bombarelli, R. GEOM, energy-annotated molecular conformations for prop- erty prediction and molecular generation.Scientific Data9, 185 (2022). 30

    2022

  111. [120]

    Siebenmorgen, T.et al.MISATO: machine learning dataset of protein-ligand complexes for structure- based drug discovery.Nature computational science4, 367–378 (2024)

    2024

  112. [121]

    G.et al.Three-dimensional convolutional neural networks and a cross-docked data set for structure-based drug design.Journal of chemical information and modeling60, 4200–4215 (2020)

    Francoeur, P. G.et al.Three-dimensional convolutional neural networks and a cross-docked data set for structure-based drug design.Journal of chemical information and modeling60, 4200–4215 (2020)

    2020

  113. [122]

    Zdrazil, B.et al.The ChEMBL database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods.Nucleic Acids Research52, D1180–D1192 (2023)

    2023

  114. [123]

    T.et al.Navigating the kinome.Nature Chemical Biology7, 200–202 (2011)

    Metz, J. T.et al.Navigating the kinome.Nature Chemical Biology7, 200–202 (2011)

    2011

  115. [124]

    Tang, J.et al.Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis.Journal of Chemical Information and Modeling54, 735–743 (2014)

    2014

  116. [125]

    I.et al.Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology29, 1046–1051 (2011)

    Davis, M. I.et al.Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology29, 1046–1051 (2011)

    2011

  117. [126]

    Liu, Z.et al.Forging the basis for developing protein–ligand interaction scoring functions.Accounts of Chemical Research50, 302–309 (2017)

    2017

  118. [127]

    P., Ye, P

    Tatonetti, N. P., Ye, P. P., Daneshjou, R. & Altman, R. B. Data-driven prediction of drug effects and interactions.Science translational medicine4, 125ra31–125ra31 (2012)

    2012

  119. [128]

    Bioinformatics36, 4316–4322 (2020)

    Deng, Y .et al.A multimodal deep learning framework for predicting drug–drug interaction events. Bioinformatics36, 4316–4322 (2020)

    2020

  120. [129]

    & Jure, L

    Marinka, Z., Rok, S., Sagar, M. & Jure, L. BioSNAP datasets: Stanford biomedical network dataset collection.http://snap.stanford.edu/biodata(2018)

    2018

  121. [130]

    Liu, H.et al.DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy.Nucleic Acids Research(2019)

    2019

  122. [131]

    Molecular Cancer Therapeutics15, 1155–1162 (2016)

    O’Neil, J.et al.An unbiased oncology compound screen to identify novel combination strategies. Molecular Cancer Therapeutics15, 1155–1162 (2016)

    2016

  123. [132]

    M.et al.The protein data bank.Nucleic acids research28, 235–242 (2000)

    Berman, H. M.et al.The protein data bank.Nucleic acids research28, 235–242 (2000)

    2000

  124. [133]

    Szarfman, A., Tonning, J. M. & Doraiswamy, P. M. Pharmacovigilance in the 21st century: new systematic tools for an old problem (2004)

    2004

  125. [134]

    Liu, Y .et al.DCDB 2.0: a major update of the drug combination database.Database2014(2014)

    2014

  126. [135]

    & Montanari, F

    Henderson, R., Clevert, D.-A. & Montanari, F. Improving molecular graph neural network explain- ability with orthonormalization and induced sparsity. InInternational Conference on Machine Learn- ing, 4203–4213 (PMLR, 2021). 31 11 Appendix In Table 3 we provide the URLs of the ...

    2021

Pith tools

Reviewed August 7, 2026 · model on record in the stance chip above.